Hims & Hers: A Telehealth Giant's Rocky Transition

Hims & Hers stock trades 70% below its high after a data breach, a forced pivot to costly branded weight-loss drugs, insider selling, and a lawsuit pressure its business model.

The stock of telehealth provider Hims & Hers is trading near $20, a staggering 70% below its 52-week high. This dramatic decline reflects a confluence of challenges, from a forced strategic pivot and a major data breach to insider selling and legal pressures, testing the resilience of its once high-flying business model.

A significant data security incident has compounded the company's troubles. Between early and mid-February, hackers infiltrated Hims & Hers's external customer service system, stealing a trove of support tickets containing personal information like names, contact details, and treatment categories. While the company states electronic health records were not accessed, management deemed the breach material enough to warrant investor disclosure. Affected users are being offered a year of complimentary identity protection services.

The core of the company's current predicament stems from a fundamental overhaul of its weight management business. Previously reliant on its own compounded medications, Hims & Hers was compelled to change course in early 2026. Regulatory pressure mounted as the FDA classified these compounds as "unapproved," and partner Novo Nordisk filed a patent infringement lawsuit. The company's response was a strategic reversal: since late March 2026, it now acts as a distributor for FDA-approved brand-name GLP-1 drugs like Wegovy and Ozempic, bundled with virtual doctor visits, nutritional coaching, and community support. Memberships start at $39 for the first month, with medication costs beginning at $149 monthly.

This pivot, however, comes with a significant financial cost. Analysts at Bank of America have slashed their price target from $23 to $21, warning of substantial risks to profitability. The shift from cheaper, self-mixed compounds to expensive branded drugs is a direct margin headwind. Experts estimate that at most, only half of the existing subscribers will transition to the higher-priced products. Consequently, Bank of America has sharply reduced its 2026 revenue forecast for the GLP-1 weight loss segment to $516 million.

Market skepticism is evident in the share price performance. The stock fell 6.1% on April 8 alone and is down roughly 40% year-to-date. Over the past six months, the decline totals 66%. This erosion of investor confidence is further dampened by actions from the C-suite. CFO Oluyemi Okupe recently sold a smaller stock package and has filed plans to sell additional shares worth approximately $4.9 million. Such pre-planned trades often proceed regardless of market conditions, but they rarely bolster sentiment during periods of weakness.

Adding to the uncertainty is a newly admitted shareholder class-action lawsuit concerning the marketing of weight loss products. This legal action ties up resources and perpetuates investor unease, particularly following the end of the Novo Nordisk partnership.

Despite these headwinds, the company's underlying operational metrics tell a story of robust growth. Revenue has soared from $527 million in 2022 to $2.35 billion in 2025, driven by its diverse portfolio addressing hair loss, mental health, sexual health, and dermatology. Its subscriber base remains strong at 2.5 million active members. For the full year 2026, management projects revenue between $2.7 billion and $2.9 billion, representing growth of 15% to 24% over the prior year. Adjusted EBITDA is expected to land in the $300 million to $375 million range.

The critical question for Hims & Hers is whether its new distribution model can sustainably support the margins of its core business, or if the loss of higher-margin compounded drugs will hurt profitability more than current estimates assume. The upcoming quarterly report may provide the first concrete evidence, but regaining Wall Street's favor will require demonstrating that margin losses in the U.S. can be swiftly offset by targeted international expansion, including through its Australian platform, Eucalyptus.